Orchard Therapeutics (NASDAQ:ORTX) announced its earnings results on Thursday. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.20), Fidelity Earnings reports.
ORTX traded down $0.10 on Friday, hitting $13.28. 74,880 shares of the company traded hands, compared to its average volume of 165,178. The stock’s 50 day moving average is $13.55. The firm has a market cap of $1.15 billion and a PE ratio of -1.30. Orchard Therapeutics has a 12-month low of $8.65 and a 12-month high of $21.64.
ORTX has been the subject of a number of research analyst reports. ValuEngine raised Orchard Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Zacks Investment Research cut Orchard Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 31st. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $23.80.
Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration.
See Also: What is the definition of a trade war?
Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.